Federico Campigotto

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Accounting for death as a competing risk in cancer-associated thrombosis studies
    Federico Campigotto
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
    Thromb Res 129:S85-7. 2012
  2. pmc A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
    Nathan J Robison
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Division of Pediatric Hematology Oncology, Department of Pediatrics, Boston Children s Hospital, Boston, Massachusetts
    Pediatr Blood Cancer 61:636-42. 2014
  3. pmc Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Br J Haematol 160:530-7. 2013
  4. doi request reprint Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin
    Ariela L Marshall
    Department of Hematology and Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Appl Thromb Hemost 21:632-8. 2015
  5. doi request reprint Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia
    Olga K Weinberg
    Department of Pathology, Children s Hospital Boston, Boston, MA, USA
    Mod Pathol 28:965-76. 2015
  6. pmc Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study
    Jeffrey I Zwicker
    Jeffrey I Zwicker, Adam Rojan, and Renee Funches, Beth Israel Deaconess Medical Center and Harvard Medical School Federico Campigotto and Donna Neuberg, Dana Farber Cancer Institute, Boston, MA Nadia Rehman and Ted Wun, University of California at Davis School of Medicine Nadia Rehman and Ted Wun, VA Northern California Health Care System, Sacramento, CA Gregory Connolly, University of Rochester Medical Center, Rochester, NY Jonathan Webster and Michael B Streiff, Johns Hopkins University School of Medicine, Baltimore, MD Anita Aggarwal, Dalia Mobarek, Charles Faselis, and Frederick R Rickles, Veterans Administration Medical Center and The George Washington University, Washington, DC and Alok A Khorana, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
    J Clin Oncol 32:1792-6. 2014
  7. doi request reprint Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis
    Andrew M Brunner
    Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
    Cancer 119:2620-9. 2013

Collaborators

Detail Information

Publications7

  1. doi request reprint Accounting for death as a competing risk in cancer-associated thrombosis studies
    Federico Campigotto
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
    Thromb Res 129:S85-7. 2012
    ..This review describes the theoretical and mathematical basis for estimating the cumulative incidence function by the competing risk model for the analysis of VTE outcomes in cancer-associated thrombosis...
  2. pmc A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
    Nathan J Robison
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Division of Pediatric Hematology Oncology, Department of Pediatrics, Boston Children s Hospital, Boston, Massachusetts
    Pediatr Blood Cancer 61:636-42. 2014
    ..We undertook a prospective, open-label, single-arm, multi-institutional phase II study to evaluate the efficacy of a "5-drug" oral regimen in children with recurrent or progressive cancer...
  3. pmc Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Br J Haematol 160:530-7. 2013
    ..Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate of VTE similar in magnitude to the lower TFMP group...
  4. doi request reprint Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin
    Ariela L Marshall
    Department of Hematology and Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Appl Thromb Hemost 21:632-8. 2015
    ..0% on dalteparin, and 14.3% on fondaparinux (P = .089). In a dedicated anticoagulation clinic, specific for patients with cancer, warfarin may be an acceptable treatment for first thrombotic events in patients with cancer...
  5. doi request reprint Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia
    Olga K Weinberg
    Department of Pathology, Children s Hospital Boston, Boston, MA, USA
    Mod Pathol 28:965-76. 2015
    ....
  6. pmc Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study
    Jeffrey I Zwicker
    Jeffrey I Zwicker, Adam Rojan, and Renee Funches, Beth Israel Deaconess Medical Center and Harvard Medical School Federico Campigotto and Donna Neuberg, Dana Farber Cancer Institute, Boston, MA Nadia Rehman and Ted Wun, University of California at Davis School of Medicine Nadia Rehman and Ted Wun, VA Northern California Health Care System, Sacramento, CA Gregory Connolly, University of Rochester Medical Center, Rochester, NY Jonathan Webster and Michael B Streiff, Johns Hopkins University School of Medicine, Baltimore, MD Anita Aggarwal, Dalia Mobarek, Charles Faselis, and Frederick R Rickles, Veterans Administration Medical Center and The George Washington University, Washington, DC and Alok A Khorana, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
    J Clin Oncol 32:1792-6. 2014
    ..Despite strong recommendations in numerous clinical practice guidelines, retrospective studies have shown that pharmacologic thromboprophylaxis is underutilized in hospitalized patients with cancer...
  7. doi request reprint Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis
    Andrew M Brunner
    Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
    Cancer 119:2620-9. 2013
    ..The authors performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to assess 5-year overall survival (OS) in various patient age groups...